As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States

5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...

Read more →

What is the value of market-wide health care price transparency?

5 September 2019 - A primary driver of high spending in the US health care system, relative to other countries, ...

Read more →

ICER's value framework and patient feedback: Q&A with Steve Pearson

15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...

Read more →

Costing methods applied to cancer

8 August 2019 - Health care is vital in improving quality and length of life.  ...

Read more →

A non-inferiority framework for cost-effectiveness analysis

24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...

Read more →

Should national pharmacare apply a value based insurance design?

22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, ...

Read more →

Ask whether a drug works before worrying about what it costs

16 July 2019 - Last week was supposed to be a turning point for drug price transparency.  ...

Read more →

Do cancer treatments have option value? Real‐world evidence from metastatic melanoma

24 June 2019 - A change in the expectations about future treatments may change the option value of a current ...

Read more →

It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...

Read more →

Novel approaches to value assessment within the cost-effectiveness framework

20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...

Read more →

Drug pricing should reflect value, not recoupment of investment

20 June 2019 - The other day I was reading a piece on reframing the conversation on drug pricing. I ...

Read more →

Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price

18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...

Read more →

New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?

12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...

Read more →

Systematic literature review calls economic impact of switching to biosimilars "uncertain"

10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...

Read more →